• Director Luke Evnin reported sales of 141,106 Werewolf Therapeutics common shares on May 27-29 under a Rule 10b5-1 plan.
• Transactions were priced at weighted averages of $0.48, $0.46, $0.45 per share.
• Indirect beneficial ownership fell to 622,579 shares following the sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001134657-26-000015), on May 29, 2026, and is solely responsible for the information contained therein.